Remove 2030 Remove Leads Remove Patients
article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Slow-release formulations were a popular choice for manufacturers, as these varieties reduce the traditional dosage frequency for patients, who only need to take these medications say, once a week. billion by 2030 appeared first on European Pharmaceutical Review.

article thumbnail

Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030

Pharmaceutical Technology

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. of 7MM sales.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

U.S. Gastrointestinal Endoscopic Devices Market Growth (2022-2030)

Medico Reach

billion by 2030. Upon immediately subjecting the patient to an X-ray, the barium appears white as doctors observe how it outlines the digestive tract. . Option to treat the patient during endoscopy. But since the patient is already sedated while performing the procedure, the doctor can treat the problem during endoscopy.

article thumbnail

Construction of major radioligand therapy manufacturing site begins

European Pharmaceutical Review

The ATLab (Alpha Therapy Laboratory) Valenciennes in Onnaing, France, will produce lead-212 radioligand therapies. So construction of the new radioligand therapy manufacturing site in France is a major step towards making these promising new treatments available to cancer patients with high unmet needs.

article thumbnail

Innovative radioligand manufacturing facility inaugurated

European Pharmaceutical Review

The first industrial-scale pharmaceutical manufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. This news follows the company beginning construction on a similar facility in France , which is set to produce lead-212 radioligand therapies for the European market.

article thumbnail

CSL doses first patient with haemophilia B gene therapy Hemgenix

Pharmaceutical Technology

CSL announced the first patient with haemophilia B has been treated with its recently approved gene therapy Hemgenix (etranacogene dezaparvovec). In the study, Hemgenix reduced or eliminated the need for prophylactic treatment in 94% of patients. Hemgenix is the first and only gene therapy approved for haemophilia B.

article thumbnail

12 Strategies to Increase Patient Engagement in Healthcare

LEVO Health

As healthcare practices strive to navigate the complexities of patient needs and preferences, the importance of fostering robust patient engagement strategies cannot be overstated. The Importance of Patient Engagement Personalization for patients is a key driver of improved healthcare outcomes.